Handel nachbörslich: 1.82 -0.01 -0.55%

Protara Therapeutics Inc (TARA)

Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten

Protara Therapeutics Inc (TARA)

Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten

Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com

Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - Yahoo Finance

Investing in Protara Therapeutics Inc (TARA) Is Getting More Attractive - Knox Daily

Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com India

Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com

Opaleye Management Inc. sells shares in Protara Therapeutics By Investing.com - Investing.com Canada

Protara reveals high choline deficiency in PS patients - Investing.com India

Protara Therapeutics Announces Results from THRIVE-1, a - GlobeNewswire

Protara reveals high choline deficiency in PS patients By Investing.com - Investing.com Canada

Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire

Protara reveals high choline deficiency in PS patients - Investing.com

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - StockTitan

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - StockTitan

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance

Analyzing Genasys Inc (GNSS) After Recent Trading Activity - Knox Daily

Check Out Protara Therapeutics Inc (TARA)’s Trade Data Rather Than the Analysts’ Views - SETE News

Investor’s Delight: Protara Therapeutics Inc (TARA) Closes Weak at 2.00, Down -0.99 - The Dwinnex

A year in review: Protara Therapeutics Inc (TARA)’s performance in the last year - US Post News

Bowhead Specialty Holdings Inc. (BOW) receives an Outperform rating from RBC Capital Mkts - Knox Daily

Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period | Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba - Barchart

Monitoring Protara Therapeutics Inc (TARA) after recent insider movements - Knox Daily

Protara Therapeutics (NASDAQ:TARA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga

TARA (Protara Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Aug. 20, 2024) - GuruFocus.com

Protara Therapeutics (FRA:1KPA) 5-Day RSI : 59.63 (As of Aug. 19, 2024) - GuruFocus.com

TARA (Protara Therapeutics) Debt-to-Revenue : N/A (As of Jun. 2024) - GuruFocus.com

TARA (Protara Therapeutics) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com

TARA (Protara Therapeutics) Peter Lynch Fair Value : N/A (As of Aug. 18, 2024) - GuruFocus.com

Protara Therapeutics (FRA:1KPA) GF Value Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com

Protara Therapeutics (FRA:1KPA) Price-to-Operating-Cash-Flo - GuruFocus.com

Protara Therapeutics (FRA:1KPA) Volatility : 109.18% (As of Aug. 17, 2024) - GuruFocus.com

Protara Therapeutics (STU:1KPA) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com

Protara Therapeutics (STU:1KPA) Forward Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com

Protara Therapeutics (STU:1KPA) 3-Year EBITDA Growth Rate : 6.50% (As of Jun. 2024) - GuruFocus.com

Protara Therapeutics (NASDAQ:TARA) Given New $25.00 Price Target at Oppenheimer - Defense World

Q3 2024 EPS Estimates for Protara Therapeutics, Inc. Increased by Analyst (NASDAQ:TARA) - Defense World

Protara Therapeutics (NASDAQ:TARA) & Elevation Oncology (NASDAQ:ELEV) Head to Head Review - Defense World

HC Wainwright Reaffirms Buy Rating for Protara Therapeutics (NASDAQ:TARA) - Defense World

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? - Simply Wall St

Protara Therapeutics price target lowered to $20 from $22 at Guggenheim - TipRanks

Protara Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News

Head to Head Review: Protara Therapeutics (NASDAQ:TARA) and Gilead Sciences (NASDAQ:GILD) - Defense World

TARA Stock Earnings: Protara Therapeutics Beats EPS for Q2 2024 - MSN

Protara Therapeutics: Q2 Earnings Snapshot - mySA

TARA Stock Earnings: Protara Therapeutics Beats EPS for Q2 2024 - InvestorPlace

Protara Therapeutics: Q2 Earnings Snapshot - Darien Times

Protara Therapeutics: Q2 Earnings Snapshot - The Advocate

Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire

Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update - StockTitan

Head to Head Survey: Protara Therapeutics (NASDAQ:TARA) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World

Oppenheimer & Co. Inc. Takes $40,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - American Banking and Market News

Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 11,396 Shares of Stock - Defense World

Opaleye Management sells shares in Protara Therapeutics worth over $27k - Investing.com India

Opaleye Management sells shares in Protara Therapeutics worth over $27k - Investing.com

Opaleye Management sells shares in Protara Therapeutics worth over $27k - Investing.com UK

Protara Therapeutics Inc (TARA) Becoming More Attractive for Investors - Knox Daily

Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 8,497 Shares of Stock - Defense World

Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 47,993 Shares - American Banking and Market News

Opaleye management sells shares worth $175,841 in Protara Therapeutics - Investing.com India

Opaleye management sells shares worth $175,841 in Protara Therapeutics - Investing.com

Autodesk COO Steven Blum sells $4.92 million in company stock - Investing.com

Opaleye management sells shares worth $175,841 in Protara Therapeutics By Investing.com - Investing.com India

Opaleye management sells shares worth $175,841 in Protara Therapeutics By Investing.com - Investing.com UK

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors - Yahoo Finance UK

Ähnlich wie TARA